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Abstract1
High-risk	 HPV	 types	 cause	 cervical	 lesions	 of	 varying	 severity,	 ranging	 from	 transient	2
productive	 infections	 to	 high-grade	 neoplasia.	 Disease	 stratification	 requires	 the	 examination	 of	3
lesional	pathology,	 and	possibly	also	 the	detection	of	biomarkers. P16INK4a and	MCM are established	4
surrogates of	high-risk HPV	E6/E7 activity, and	 can	be	 extensively	 expressed	 in	high-grade	 lesions.5
Here	we	have	combined	these	two	cellular	biomarkers	with	detection	of	the	abundant	HPV-encoded	6
E4	protein	in	order	to	identify	both	productive	and	transforming	lesions.	This approach has	allowed us	7
to	distinguish	true	papillomavirus	infections	from	similar	pathologies,	and	has	allowed	us	to	divide	the	8
heterogeneous	CIN2	category	into	those	that	are	CIN1-like	and	express E4,	and	those	that	more	closely	9
resemble	 non-productive	 CIN3.	 To	 achieve this,	 530	 lesional	 areas	 were	 evaluated	 according	 to	10
standard	pathology	criteria and by	using	a	multiple	staining approach	that	allows us	to	superimpose	11
biomarker	patterns	 either	 singly	or	 in	 combination	onto	 an annotated	haematoxylin	&	eosin	 image.	12
Conventional	 grading	 of	 neoplasia	 was	 established	 by	 review	 panel,	 and	 compared	 directly	 to	 the13
composite molecular	pathology	visualised	on	 the	same	tissue	section.	The	detection of	E4	coincided	14
with	the	onset of	vacuolation,	becoming	abundant	in	koilocytes	as	the	MCM	marker	declined	and	cells	15
lost	 their	 defined	 nuclear	 margins as	 visualised	 by standard H&E	 staining.	 Of	 the	 dual	 marker	16
approaches,	 p16INK4a and	 E4	 appeared	most	 promising, with	 E4	 generally	 identifying	 areas	 of	 low-17
grade	disease	even	when	p16INK4a was	present.	Extensive	p16INK4a expression	usually	coincided	with	an	18
absence	of	E4	expression	or its	focal	retention	in	sporadic	cells within	the	lesion.	Our	results	suggest	19
that	a	straightforward	molecular evaluation	of	HPV	 life-cycle	deregulation	 in	cervical	neoplasia	may	20
help	 improve	 disease	 stratification,	 and	 that	 this	 can	 be	 achieved	 using complementary	 molecular	21
biomarker pairs such	 as	 MCM/E4	 or	more	 promisingly,	 p16INK4a/E4 as	 an	 adjunct	 to	 conventional	22
pathology.23
24
25
26
27
28
29
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Introduction1
The	 International	Agency	 for	Research	on	Cancer	states	 that	4.8%	(610,000)	of	new	cancers	2
occurring	 in	 2008	 worldwide	 were	 attributable	 to	 human	 papillomavirus	 (HPV) infection,	 with	3
substantially	 higher	 incidence	 and	mortality	 rates	 in	 developing	 versus	 developed	 countries	 (1,	 2).	4
HPV has	a	causal	aetiology	for	cancers	of	the	cervix	uteri,	penis,	vulva,	vagina,	anus	and	oropharynx,	5
including	the	base	of	the	tongue	and	tonsils	(3,	4).	To	date,	more	than	200	different	types	of	HPV	have	6
been	 identified	 on	 the	 basis	 of	 sequence	 analysis	 (http://pave.niaid.nih.gov/#home,	 (5)),	with	 each	7
type	showing	a	defined	epithelial	tropism	and	disease	association (3,	6).	High-risk	Alpha	HPV	(high-8
risk	HPV)	types	are	the	primary	cause	of	cervical	neoplasia	and	cervical	cancer,	a	disease	that affects	9
over	half	a	million	women	per	year	worldwide	(3,	7,	8).10
In	 squamous	 cervical	 epithelium,	 the	mitotically	 active	basal	 and	parabasal	 cells	 occupy	 the	11
cell	 layers	immediately	above	the	basal	lamina	(9).	As	cells	enter	the	mid	zone,	they	begin	to	mature,	12
and	 show	 a	 general	 increase	 in	 the	 volume	 of	 clear	 vacuolated	 cytoplasm	 containing	 glycogen.	 The	13
differentiated superficial	 cells	 are	 characterised	 by larger areas	 of	 cytoplasm	 and	 smaller	 pyknotic	14
nuclei	 (10),	with	 the HPV	 life	cycle	being linked	to	 the	differentiation	status	of	 this	epithelium.	HPV	15
infects	 actively	 dividing	 basal	 cells	 during	 wound	 healing	 (11),	 with	 the	 viral	 genome	maintaining	16
itself	episomally	at	a	low	copy	number.	In	the	lower	epithelial	layers,	high-risk-HPV	express	E6	and	E7	17
proteins	in	order	to	stimulate	cell	proliferation	and	to	ensure	that	differentiating	cells	are	retained	in	18
the	cell	cycle	(12,	13).	These viral	proteins stimulate	the	synthesis	of	cellular	proteins	necessary	for	S-19
phase	entry,	allowing	the	replication	of	viral	episomes	and	initiation	of	the	productive	viral	phase.	As	20
virus-infected	cells	approach	 the	 epithelial	surface,	an	 increase	 in	 late	promoter	activity	 leads	 to	an	21
elevation	 in	 replication	 (E1,	 E2),	 and	 accessory	 proteins	 (e.g. E4),	 followed	 by	 the	 assembly	 of	22
infectious	 virions	 in	 the	 superficial	 cell	 layers	 (3).	 Current	 thinking	 suggest	 that	 the	 levels	 and/or	23
activity	 of	 E6	 and	 E7	 are	 lower	 in	 CIN1	 (low-grade	 squamous-intraepithelial	 lesion	 (LSIL) or mild	24
dysplasia)	 where	 basaloid	 cells	 occupy	 the	 lower	 third	 of	 epithelium,	 than	 in	 CIN2/3	 (high-grade	25
squamous-intraepithelial	 lesion	 (HSIL)	 or	 moderate	 to	 severe	 dysplasia),	 where	 such	 cells	 occupy	26
from	two-thirds	to	the	full	thickness	of	the	epithelium (14).	Such	deregulated	viral	gene	expression	is	27
thought	 to	 underlie pathologic	 phenotype,	 and	 predisposes	 the	 cell	 to	 the	 accumulation	 of	 genetic	28
errors	and	the	eventual	progression	to	cancer (14). High-grade	CIN	(CIN2/3;	HG-CIN) lesions	often	do	29
not	support	a	productive	virus	life-cycle,	but	represent	a	transforming	viral	phase	or	abortive	virus	life	30
cycle,	even	though	the	majority	of	cells	within	the	lesion	still	maintain	intact	viral	episomes	(15,	16).	31
Most	cervical	HPV	infections	are	cleared within	1-2	years. However,	women	with	persistent	high-risk	32
HPV	 infections can	 develop	 HG-CIN (17-19).	 Current	 treatments	 for	 HG-CIN	 focus	 on	 eliminating	33
abnormal	 HPV-infected	 precancerous	 cells	 by	 surgical	 excision.	 The	 use	 of	 molecular	 criteria	 that	34
distinguish	lesions	supporting	an	abortive or	transforming, rather than	a	productive	phase	could	thus	35
be	of	value	in	clinical	practice (20).36
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Our	understanding	of	the	molecular	biology	of	HPV	infection	and	the	organisation	of	the	HPV	1
life-cycle	during	cancer	progression	provides	a	rational	basis	for	marker	selection	(21).	A	major	class	2
of	 biomarkers	 useful	 in	 cervical	 screening	 represents	 proteins	 activated	 as	 a	 consequence	 of	3
expression	 of	 the	 viral	 oncogenes	 E6	 and	 E7.	 E7	 associates	 with	 the	 Rb cell	 cycle	 regulator	 and	4
releases	 the	 E2F	 transcription	 factor,	 which subsequently	 activates genes	 necessary	 for	 DNA	5
replication (22).	 The	 most	 extensively	 evaluated	 cell	 cycle	 markers	 include	 p16INK4a,	 MCM	6
(minichromosome	 maintenance	 protein),	 and	 Ki-67	 (23-25).	 When	 present	 in	 the	 upper	 layers	 of	7
cervical	lesions,	these	proteins	can	be	regarded	as	surrogate	markers	of	viral	oncogene	expression	(26,	8
27).	 In	 low-grade	cervical	 lesions,	such	proteins	are	 typically	confined	to	 the	 lower	epithelial	 layers,	9
but	extend	into	the	higher	epithelial	 layers	in	HSIL.	Marked	inter-and	intra-observer	variability	even	10
on	histology	indicates	the	need	for	biomarkers	that	are	specific,	sensitive	and	reproducible	(23,	24).	11
The	purpose	of	this	study	was	to	correlate	the	two	most	widely	used	molecular	surrogates	of	12
E6/E7	expression	and	life-cycle	deregulation	(p16INK4a and	MCM)	with	detection	of	the	abundant	HPV13
E4	protein,	which	is	highly	expressed	in	productive	HPV	infections	and	which	marks	the	initiation	of	14
the	late	stage	of	the	virus	life	cycle.	Previous	studies	have	suggested	that	these	two	distinct	classes	of	15
biomarker	 are	 complementary	 and	 that	 they	 could be	used	 together	 to	 establish	 grade	of	neoplasia	16
and	to	distinguish	virus	infections	from	other	similar	pathologies	that	may	have	a	different	prognosis	17
(12,	 28).	 In	 this	 study	we	 have	 correlated the	 expression	 of	 all	 three	 biomarkers	 with	 the	 precise	18
pathology	 characteristics	 that	 are	 currently	 used	 to	 establish	 lesion	 grade,	 in	 order	 to	 establish	19
whether	 a combined molecular	 and	 standard	 pathology	 approach	 might	 offer	 advantages	 over	20
conventional	methods	in	the	future.	To	do	this we	have	carried	out	multiple	biomarker	stains	on	tissue	21
sections containing	different	 grades	of	neoplasia,	 followed	by	 the	digital	 overlay	of	 each	biomarker	22
pattern	either	singly	or	in	combination	onto	the	haematoxylin	and	eosin	(H&E)	pathology.	Our	results	23
indicate	 that	a	dual	 biomarker	approach	using	E4	 and	p16INK4a can	distinguish	HPV-associated	CIN1	24
from	other,	probably	non-viral	pathologies,	and	may	be	used	to	divide	the	CIN2	group	according	to	the	25
extent	of	life-cycle	deregulation.26
27
Materials	and	methods28
Clinical	samples	29
Loop	 electrosurgical	 excision	 procedure	 (sometimes	 referred	 to	 as	 LEEP)	 and	 hysterectomy	30
specimens	 from	women	treated	at	 the	 Jagiellonian University	Medical	College,	Krakow,	Poland (103	31
biopsy	 specimens),	 as	 well	 as	 punch	 biopsies	 taken	 from	 women	 during	 colposcopy	 at	 the	32
Gynaecological	 outpatient	 clinic	 of	 Hospital	 Clínic,	 Barcelona,	 Spain	 and	 Reinier	 de	 Graaf	 Groep,	33
Voorburg,	the	Netherlands (34	biopsy	specimens), were	used	in	this	study	(29).	Patient	data	for	all	the	34
samples	was	anonymised.	All	biopsies	were	fixed	in	buffered	formalin	and	embedded	in	paraffin.	35
36
Selection	of	cervical	biopsy	sections and	whole	tissue	PCR	37
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Twenty	 five serial	 sections	of	5	µm	were	 cut	 from	each	 formalin-fixed	paraffin-embedded	histology	1
specimen. Sections	 8	 and	 15	 were	 taken	 for	 whole	 tissue	 section-PCR	 analysis	 and	 analysed	2
separately, and sections	12,	13,	and	14	were	mounted	on	Laser	Capture	Microscopy	membrane	slides3
(Zeiss, Cambridge,	UK).	Slide	11	was	used	for	E4	Mab	and	MCM2	immunohistochemistry	followed	by	4
p16INK4a and	 H&E	 staining.	 Slide	 10	 was	 used	 for	 pan	 E4	 monoclonal	 and	 MCM25
immunohistochemistry followed	 by	 H&E	 staining.	 Extensive	 measures	 were	 implemented	 during	6
sectioning	to	prevent	cross-contamination.	7
8
Immunohistochemical	staining9
E4	detection	was	carried	out	using	both TVG	405	(a	HPV16,18,	31,	35	and	45-specific	E4	Fab	(28)) and10
a	newly	developed	pan-specific	E4	monoclonal	 antibody	 (FH1.1)	 reactive	 against	 the	high-risk	HPV	11
types	 16,	 18,	 31,	 33,	 35,	 39,	 45,	 51,	 52,	 53,	 56,	 58,	 59,	 66,	 67	 and	 70 (manuscript	 in	preparation),	12
depending	on	the	HPV	types	present.		Although	TVG	405	was	used	for	the	majority	of	the	stains,	both	13
antibodies	 produce	 equivalent	 staining patterns. MCM2	 and	 p16INK4a immunohistochemistry was	14
performed	 on all cervical	 biopsy	 sections	 according	 to	 standard	 procedures.	 For	 epitope	 retrieval,	15
slides	were	incubated	in	solution	D	pH	9.0	(Dako,	Glostrup,	Denmark)	for	10	min	at	room	temperature	16
prior	to	autoclaving	for	2	min	at	121°C.	The	HPV	anti-E4	Fab	TVG	405 was	directly	conjugated	to	Alexa	17
488	 and	was	diluted	 150-fold	 prior	 to	 use.	 The	 concentrated	monoclonal	 E4	 antibody	 (FH1.1)	was	18
diluted	 100-fold and	 detected	 using	 an	 anti-mouse	 Alexa	 488	 conjugated	 antibody	 (dilution	 1:150,	19
Vector,	Peterborough,	UK).	E4	staining	was	combined	with MCM2	using	a	primary	rabbit	polyclonal	20
antibody to	MCM2 (Abcam,	Cambridge,	UK).	MCM	antibody	detection	was	carried	out	using	an	anti-21
rabbit	Alexa	594	conjugated	antibody (dilution	1:150,	Vector,	Peterborough,	UK). Nuclear	counterstain	22
was	performed	with	4’-6-diamidino-2-phenylindole	(DAPI,	1	mg/ml	200- to	500-fold	diluted,	Sigma,	23
St-Louis,	MO,	USA)	before	mounting	in	Citifluor	medium	(Agar	Scientific,	Essex,	UK)	for	fluorescence	24
scanning	and	digital	imaging	on	a	Pannoramic	Slide	Scanner (3D	Histotech,	Hungary).25
Sections	which	 had	 been	 stained	with	 the	 Fab	 fragment	 to	HPV	 E4	 and	 a	 rabbit	 polyclonal	26
antibody to	MCM2 were	 then	 stained	using	 a	mouse	primary	 antibody	 to	p16INK4a clone	 JC8	diluted	27
1:20	 (Santa	Cruz	Biotechnology	 Inc.,	 Santa	Crua,	 CA,	USA)	which	was	detected	using	 an	 anti-mouse	28
biotinylated	 antibody	 (dilution	1:150,	Vector,	 Peterborough, UK)	 followed	by	development	using	 an	29
ABC	kit	(Vector)	and	red	AEC-reagent	(Sigma,	St	Louis,	USA).	After	scanning and	digital	imaging of	the	30
p16INK4a stain	(using	the	Pannoramic	Slide	Scanner (3D	Histotech,	Hungary)	as	described	above),	slides	31
were	H&E	stained	with	Carazzi	Haematoxylin	(x2) prior	to	rescanning	under	bright	field	illumination.32
For	p16INK4a,	strong	nuclear	and	cytoplasmic	staining	was	considered	as	positivity.	For	MCM2,	33
strong	nuclear	staining	was	considered	as	positivity. The	p16INK4a and	MCM2	results	were	reported	in	34
a	semi-quantitative	fashion	as	negative	or	focal	staining,	staining	up	to	1/3	of	the	epithelium,	staining	35
up	to	2/3	of	the	epithelium	or	staining	above	2/3	of	the	epithelium.	Scoring	was	based	on	the	highest	36
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category	within	an	annotated	area.	The immunohistochemistry staining	and	reading	was carried	out	1
by	three	individuals	(HG,	YS	and	RvB).2
3
HPV	DNA	detection	and	laser	capture	micro-dissection4
HPV	 typing	 was	 carried	 out	 on	 all	 cases	 using	 a	 PCR/Line	 Probe	 Assay	 (SPF10-PCR-DEIA-LiPA25 ,	5
Version	1,	Labo	Biomedical	Products	BV,	Rijswijk,	The	Netherlands) as	described	previously (30,	31)6
in	order	to assign HPV	type(s)	to	a	lesion. 		This	is	referred	to	in	the	text	as	whole	tissue	section	whole	7
tissue	section-PCR.	 	 In	CIN1	areas	 that	were	E4-negative, an	adjacent	section	was	analysed	by	 laser	8
capture	microdissection-PCR	 in	order to	 establish	whether	HPV	DNA	was	detectable	 in	 the	 lesional	9
area	(32).	Fluorescence	 in	situ hybridisation	(FISH) was	carried	out	on	a	subset	of	these	E4-negative	10
lesions	(including	all	the	total-agreement	CIN1	cases)to	confirm	that	E4-negativity	correlated	with	an	11
absence	of	genome	amplification (12,	33).		Sequence	analysis	of	the	SPF10 regions	was	done	for	three	12
of	 the	 laser	 capture	 microdissection regions that	 remained	 untypeable by PCR/Line	 Probe	 Assay13
(LiPA25) as	described	previously (34). We	excluded	cases	with	HPV	types	 that were	undetectable	by	14
the	antibodies	used	in	this	study.	15
16
Pathological	diagnosis	and	grading17
Initial	diagnosis	and	 the	grading	of	discrete	areas	with	different	pathologies	was	carried	out on	the	18
H&E	 stained	 section	 according	 to	 standard	 criteria	 by	 an	 expert	 pathologist	 at	 UCL (London,	 UK).	19
Annotated	regions	were	classified	as	‘non-CIN’, when	HPV-associated	pathology	was	absent, but	where	20
other histological	 changes,	 including	 immature	 metaplasia and squamous	 hyperplasia were	 seen.		21
When putative	HPV-associated	changes	were	noticed,	they were	classified	either as CIN1,	CIN2,	CIN3	22
or	a	combination	thereof (e.g.	CIN1/2,	CIN2/3). Grading	was	then	independently	re-assessed	by	two	23
expert	 pathologists	 using the	 same	 tissue	 section.	 Discrete	 areas	 within	 the	 tissue	 section	 were	24
examined	in	this	study,	because	we	wanted	to	correlate	the	precise	relationship	between	markers	of	25
infection	and	associated	pathology,	although	we	appreciate	that	in	routine	practice,	the	highest	grade	26
of	disease	on	the	tissue	section	must	be	used	to	determine	treatment	options. If	all	pathologists	agreed	27
on	the	diagnosis of	disease	severity,	it	was	considered	as	total	agreement.	If	2/3	pathologists	agreed,	it28
was	 considered	 consensus	 agreement.	 	 Furthermore,	 all	 areas	 were	 scored	 for	 the	 presence	 of	29
koilocytosis	 (i.e.	 superficial	 cells	 with	 perinuclear	 atypia	 and	 cytoplasmic	 cavitation	 (see	 p209	 of	30
reference (10)),	 or	 the	 presence	 of	 vacuolation,	 when	 not	 all	 the	 koilocyte	 characteristics	 were	31
apparent. The	pathologists	were	blinded	to	the	HPV	status	and	immunohistochemistry	results.32
33
Results	34
35
Development	of	an	Overlay	Approach	for	Pathology/Biomarker	Correlation	36
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In	order	 to	correlate	 the	expression	patterns	of	multiple	biomarkers	with	disease	pathology,	1
we	 first	 developed	 an ‘image-overlay’	 approach.	 Using	 this	 methodology,	 the	 distribution	 of	 key	2
molecular	markers	were imaged	and	captured	separately	 following	 immunofluorescence	staining	or	3
immunohistochemistry (Fig.1A).	Our	marker	panel	included	p16INK4a,	which	is	an	established	marker	4
of	 deregulated	 high-risk	HPV	 gene expression,	 and	MCM, which	 identifies	 cells	 ‘in	 cycle’.	 	 Both	 are	5
considered	as	surrogates	of	E6/E7	expression	when	present	in	HPV-associated	cervical	neoplasia. An	6
important	aspect	of	this	study	is	the	use	of	such	markers	in	combination	with	the	E4	biomarker,	which	7
represents	a	separate	category	of	marker that marks	the	onset	of	productive	infection.	 	The	staining	8
and	 image-capture	 regime	 is	 shown	 in	Fig.1A.	 At	 the	 end	of	 this	procedure,	 the	 tissue	 section	was	9
cleared	 of	 visible	 biomarker	 staining	 as	 part	 of	 the	 H&E staining	 regime in	 order	 to	 allow	 precise	10
visualisation	 of	 the	 pathology	 features	 used	 in	 conventional	 diagnosis.	 To	 accurately	 correlate	11
molecular	biomarker	patterns	with	disease	pathology,	all	of	the	H&E-stained	slides	were	subsequently	12
subjected	 to	 pathology	 review,	 and	 discrete	 lesional	 areas exhibiting	 distinct	 pathologies	 were	13
annotated	 as	 shown	 in	 Fig.1A.	 Individual	 biomarkers were	 then	 digitally	 superimposed	 onto	 the	14
annotated	H&E	image	in	order	to	establish	the	molecular	pathology	of	disease.	The	images	shown	in	15
Fig.1B	shows	the	distribution	of	E4	(coloured	green)	in	regions	of	low-grade	disease,	the	distribution	16
of	MCM	(coloured	red), which	marks	cells	in	cycle,	and	the	distribution	of	p16INK4a (coloured	brown)	17
which	is	most	prominent	in	the	regions	of	HG-CIN.	As the	molecular	biomarker	stains	and	H&E	are	all	18
carried	out	on	the	same	tissue	section,	individual	markers	can	be	overlayed	in	different	combinations	19
to	fully	understand	how	HPV	activity	and	cellular	gene	expression	relates	to	conventional	pathology.	20
The	complementarity	of	the	HPV	E4	biomarker	(green),	and	surrogate	markers	of	E6/E7	expression	21
(p16INK4a (brown)	 and	MCM	 (red))	 is	 shown in	 the	 low-power	 images	 in	 Fig.1B,	 as	 are	 the	 distinct	22
biomarker	distributions	seen	in	low	and	high-grade	disease	areas.	During	the	course	of	the	study,	530	23
areas	with discrete	cervical	pathologies	(as	shown	in	Fig.1A)	were	identified	and	analysed	using	the	24
biomarker-overlay	approach.	25
26
Pathology	Agreement27
Of	the 530	annotated	regions	examined	in	this	study,	all	pathologists	agreed	on	the	diagnosis	in	146	28
instances, while	in	282	areas there	was	a	consensus by	2/3	pathologists.	102	lesional	areas	were	the	29
subject	of	total	disagreement,	with	pathologists	disagreeing	as	to	the	precise	CIN	grade	(e.g.	CIN1	or	30
CIN2,	or	CIN2	or	CIN3)	or	whether	diagnosis	should	be	CIN1	or	non-CIN	(i.e.	metaplasia,	inflammation	31
etc).	 In	 total,	 276 lesional	 areas (52%)	were	 classified	 as	 CIN1	 by	 at	 least	 one	 pathologist.	 Only	 in	32
25/276 (5%)	areas	was	 there	 total agreement	on	 the	CIN1	diagnosis however,	with	an	additional	833
areas	receiving	a	range	of	diagnosis	comprising	CIN1/2.		284 lesional areas	were	classified	as	CIN2	by	34
at	least	one	pathologist,	but	in	only	12/284 (4%) did	all	three	pathologists	agree	on	the	diagnosis.	In	635
of	 these,	 one	 of	 the	 pathologists	 used	 either	 a	 CIN2/CIN3	 (4 areas)	 or	 a	 CIN1/CIN2	 (2 areas)	36
classification.		A	total	of	311 individual	areas	were	classified	as	CIN3	by	at	least	one	pathologist,	but	in	37
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only	 68 areas	was	 there	 total	 agreement	 on	 the	 CIN3	 diagnosis amongst	 all	 three	 pathologists.	 	 Of	1
these,	23	received	a	diagnosis	of	CIN2/CIN3	by	one	of	the	pathologists.	The	areas	with	total	agreement	2
were	subsequently	used	to	establish	the	specific	criteria	that	might	allow	the	use	of	molecular	markers	3
as	surrogates	of	CIN grading. HPV-typing analysis revealed that	the	majority	of	cases	(90%)	contained4
only	a	single	HPV	type	by	whole	tissue	section-PCR,	and	encompassed	single-infections	by	HPV	types	5
16,	18,	31,	33,	35,	39,	51,	52,	53,	56,	58,	59	and	66. No	additional	types	were	detected	in	cases	with	6
multiple	infections,	which	contained	between	two	and	five	HPV	types,	all of	which	could be	detectable7
using	the	combination	of	E4	antibodies	outlined	in this	study.	8
9
Total	Agreement	CIN1	Generally	has	a	Well-Defined	Molecular	Pathology	Pattern10
HPV-induced	 changes	 are	 considered	 pathognomonic	 of	 low-grade	 squamous-intraepithelial	11
lesions,	and	of	these	the	most	significant	is	nuclear	atypia	characterized	by	variation	in	nuclear	size,	12
hyperchromasia,	and	irregularity	or	wrinkling	of	the	nuclear	membrane. Additional	characteristics	of	13
HPV	 infection	 include	 acanthosis and	 koilocytosis.	 The	 33 CIN1 regions examined	 here	 had	14
recognisable	characteristics,	with	koilocytosis	and	clear	evidence	of	cytoplasmic	vacuolation	in	32 of	15
the	areas	(see	Fig.2A(i)	and	2A(ii)).	The	majority	of	these	‘total-agreement’	CIN1	lesions	(i.e.	27	out	of	16
33	(82%)),	showed	expression	of	the	E4	biomarker	(Fig.2A(i)	and	(ii)),	although	in	3 areas	there	was	17
tissue	damage	at	the	epithelial	surface	that occurred	during	the	biopsy procedure	or	during	histologic	18
processing).	In	contrast	to	the	unambiguous	CIN1	shown	in	Fig.2A(i)	and	2A(ii),	the	lesion	shown	in	19
Fig.2A(iii)	was	diagnosed	 as	 CIN1/basal	 cell	 hyperplasia	 by	 one	 of	 the	 three	 pathologist	 reviewers.	20
HPV52 was	detected within	the	 tissue	by	 laser	capture	microdissection,	but	this	was	at	the	 limits	of	21
detection	 compared	 to	 the	 productive	 CIN1	 cases	 described	 above,	 requiring	 DNA	 sequencing	 to	22
confirm the infecting	type	as	HPV52.	Only	five	other	CIN1 lesions	were	found	to	be	devoid	of	E4,	with	23
one	of	these	being	reclassified	as	higher	grade	(CIN3)	following	visualisation	of	mitotic	figures in	the	24
upper	epithelial	third	on	pathology	review,	as	well	as	nuclear	atypia	in	the	basal	layer despite	a	low-25
grade	 pathology	 in	 the	mid-epithelial	 layers. The	 presence	 of	 p16INK4a and	MCM2	 expression	 in	 the	26
upper	two-thirds	of	the	epithelium,	and	the	absence	of	E4	supported	this	revised	grading.	 As	reported	27
previously,	 the	 presence	 of	 E4	 correlated	 closely	 with	 the onset	 of	 viral	 genome	 amplification	 as	28
visualised	by	fluorescent	in	situ hybridisation	(FISH) (6,	12,	33).			Viral	genome	amplification	was	not	29
seen	 in	 any	 of	 the	 6	 E4-negative	 CIN1	 described	 here.	 	 Two	 of	 the	 CIN1	 E4-negative	 areas	 were	30
tangentially	 sectioned and	 thus	 difficult	 to	 interpret,	 while	 one	 showed	 clear	 inflammation.	31
Interestingly,	 the	remaining	E4-negative	CIN1	was	amongst	 those	classified	as	CIN1/2	by	one	of	 the	32
pathologists	 (shown	 in	 Fig.2B	 (iii))	 and	 differed	markedly	 from	 the	 above	 examples,	 in	 containing	33
clearly	identifiable	koilocyte-like	cells	that	are	suggestive	of	productive	HPV	infection	(Fig.2B	(iii)),	but	34
only	 limited	MCM2	and	p16INK4a expression	which	was	restricted	to	 the	basal	and	suprabasal	 layers	35
(MCM2	staining	shown	in	Fig.2B	(iii)).	In	the	koilocyte-like	cells	(arrowed	in	Fig.2B(iii))	there	was	no	36
evidence	 of	 cell-cycle	 entry,	 viral	 genome	 amplification	 (as	 determined	 by	 fluorescence	 in	 situ37
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hybridisation;	data	not	shown)	or	the	presence	of	E4	(see	Fig.2B	(iii)),	distinguishing	this	lesion	from	1
the	majority	of	productive	CIN1,	which	were	E4-positive	(see	Fig.2B(i)	and	2B(ii)),	and	which	could	be	2
confirmed	as	productive HPV	infections.	Although	HPV type	33	could	be	detected	in	this	lesion	by	laser	3
capture	microdissection,	 it	 is	worth	 noting	 that	HPV	 can	 sometimes	 also	 be	 detected	 in	 apparently	4
normal	cervical	tissue	as	an	asymptomatic	or	latent	infection	(32,	35),	and	that	HPV	positivity	in	CIN1	5
can	be	between	50-70%	(36). In	the	absence	of	a	definitive	pathognomic	biomarker	pattern	or	other	6
evidence	of	viral	gene expression,	viral	causality	remains	uncertain.	7
8
HPV_E4	Accumulation	in	CIN1	Occurs	during	Vacuolation	and	Koilocyte	Development9
To	 correlate	 virus-associated	 pathology	 with	 biomarker	 presence	 more	 precisely,	 the	10
E4/MCM2	 biomarker	 pair	was	 overlayed	 onto H&E	 stained	 images	 in	 all	 of	 the	 low-grade	 lesional	11
areas	described	above.	This	analysis	revealed	a	reproducible	relationship	between	marker	presence	12
and	viral pathology	(Fig.2B).	Cells	with well	defined	nuclear	margins, before	the	first	appearance	of	E4	13
stained	strongly	with	MCM2	(cells	 labelled	‘1’	 in	Fig.2B	(i)	and	(ii)). The	appearance	of	E4	coincided	14
with	the	first	signs	of cellular	vacuolisation	in	HPV	associated	CIN,	with	vacuolisation	becoming	more	15
apparent	in	these	E4-positive	cells	upon further	differentiation	(cells	labelled	‘2’ in	Fig.2B	(i)	and	(ii)).	16
E4	was	typically	more	apparent	in	koilocytic	cells	however	(labelled	‘3’	 in	Fig.2B), which	we	suspect	17
arise	 from	these	 first	E4-positive	vacuolated	cells. The	koilocytotes and	the	cells	 immediately	above	18
them	accumulate higher	levels	of	the	E4	biomarker and lose	their	well-defined nuclear	margins	in	the	19
H&E	stain,	with lower	and	more	diffuse	MCM2	expression	(cells	labelled	‘4’	in	Fig.2B	(i)	and	(ii)).	The	20
larger	nuclear	size	often	seen	in	these	cells	is	compatible	with	what	might	be	expected	following	cell	21
cycle	arrest	in	G2,	which is	thought	to	be	required	for	genome	amplification	and	E4	accumulation (37).22
Interestingly,	a	subset	of	CIN1	showed	a	noticeable	elevation,	rather	than	decline	in	MCM2	expression	23
as	 the	E4	biomarker	 appeared,	with	 little	 basal	 cell	 expression	 (data	not	 shown), similar	 to	what	 is	24
occasionally	 seen	 in HPV16	organotypic	 raft	 cultures	 (14).	This	 is	 reminiscent	of	 benign	productive	25
lesions	 (i.e.	 warts)	 caused	 by	 low-risk	 papillomaviruses. When	 taken	 alongside	 the	 variation	 in	26
p16INK4a staining	patterns	seen	 in	CIN1,	 the	data	suggests	some	variation	 in	viral	gene	expression	in	27
CIN1.	28
These	 distinctive	 biomarker	 correlations	were	 not	 apparent	 in	 the	 atypical	 CIN1/CIN2	 (see	29
koilocyte-like	cells	marked	by	‘K’	in	Fig.2B	(iii)).	Interestingly,	the non-productive	infection	shown	in30
Fig.2A(iii)	shows	(upon	close	inspection)	only	the	very	first	signs	of	koilocyte	formation,	in	agreement	31
with	 its	 distinct	 molecular	 pathology.	 While	 MCM2	 and	 p16INK4a staining	 have	 very	 similar	32
distributions	 here,	 in	 productive	 HPV	 infections	 such	 as	 that	 shown	 in	 Fig.2A(ii),	 robust	 MCM2	33
expression	persists	into	the	upper	epithelial	 layers	beyond	those	where	p16INK4a is	found.	Given	that	34
MCM	 is	 a	 marker	 of	 E6/E7-mediated	 cell	 cycle	 entry	 in	 such	 lesions,	 and	 that	 cell	 cycle	 entry	 is	35
required	for	genome	amplification,	this	pattern	fits	well	with	our	understanding	of	the	HPV	life	cycle	36
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organisation.	By	contrast,	p16INK4a is	considered	to	be	a	marker	of	deregulated	E6/E7	gene	expression,	1
which	may	account	for	its	more	limited	distribution.2
3
Diagnostic	Relevance	of	the	HPV_E4	biomarker	in	p16INK4a/MCM-positive	CIN3	4
In	 63 cases	 where	 there	 was	 total	 agreement	 on	 the	 CIN3	 diagnosis	 (out	 of	 68),	 no	 E4	 could	 be	5
detected	by	any	of	the	E4	antibodies	used	in	this	study.	P16INK4a and	MCM expression	extended	from	6
2/3	 of	 the	 epithelium	 up	 to	 the	 surface	with	 nuclear	 crowding,	 pleomorphism	 and	 loss	 of	 polarity	7
clearly	 visible (Fig.	 3A(i)	 and	 (ii)).	Although	 absence	 of	 the	 E4	 biomarker	 was	 by	 far	 the	 majority	8
pattern	 in	 the	 CIN3	 group,	 two	 of	 the	 E4-negative	 cases	 were	 also	 p16INK4a-negative,	 even	 though	9
MCM2	 levels	 extended	 to	 above	 2/3	 of	 the	 epithelium.	 Amongst	 the five	 CIN3 areas	where	 E4	was	10
detected,	the	majority	(i.e.	4 out	of	5)	contained	only	single	E4-positive	cells,	or	small	clusters of	such	11
cells	 in	 isolated	 regions	of	differentiation	 close	 to	 the	 epithelial	 surface.	These	 isolated	 cells	 or	 cell-12
groups	generally	showed	some	evidence	of	koilocytosis	and	viral	cytopathic	effect,	similar	to	what	is	13
found	more	 extensively	 in	 low-grade	disease,	 (cells	marked	by	 arrows	1	 and	2	 in	Fig.3C	 (panel	B)),	14
although	 it	was	notable	 that	not	 all	 vacuolated	 cells	were	E4-positive	 (cells	marked	by	 arrow	 ‘v’	 in	15
Fig.3C	 (panel	A)).	Only	 in	one	CIN3	was	 E4	 expression	extensive,	 and	 in	 this	 case	 the	 lesional area	16
exhibited	 some	 degree	 of	 tangential	 sectioning with	 mixed	 or	 heterogeneous	 pathology.	 MCM	17
expression	 extended	 throughout	 the	 epithelium	 and	 facilitated	 the	 visualisation	 of	 nuclear	 atypia,	18
nuclear	 crowding	 (as	 seen	 in	 Fig.3B(ii)),	 pleomorphism	 and	 loss	 of	 normal	 cell	 polarity.	 P16INK4a19
expression	was	typically	found	to	extend	from	between	two-thirds	of	the	epithelium	up	to	the	surface	20
and	was	broadly	complementary	to	the	pattern	of	staining	seen	with	E4	(Fig.3A	and	B).	21
22
Division	of	the	CIN2	Group	according	to	HPV_E4	and	p16INK4a/MCM2	Biomarker	Patterns	23
Studies	of	 the	pathological	 diagnosis	 of	CIN2	have	 shown	that	 it	 is	 only	poorly	 reproducible	24
(38). The	E4	biomarker	was	apparent	in	7/12 (58%)	CIN2	areas with	total	agreement,	using	both	E4	25
antibodies	described	 in	this	study.	Staining	 for	E4	was	however	often	patchy,	being	 interspersed	by	26
regions	 where	 p16INK4a and	 MCM	 clustered	 close	 to	 the	 epithelial	 surface	 (see	 Fig.4A).	 This	 was	27
particularly	evident	when	the	areas	designated	as	CIN2	were	large.	4 of	the	E4-positive	areas	showed	28
prominent	 koilocytosis,	 with	 E4	 being	 expressed	 in	 a	 subset	 of	 koilocytes upon	 epithelial	29
differentiation	(Fig.4A	and	5A).	P16INK4a levels	extended	up	to	and	above	2/3	of	 the	 epithelium.	The	30
MCM	marker	typically	extended	into	the	upper	two	thirds	of	the	epithelium.31
Interestingly, 5 of	 the	agreed	CIN2	areas	were	E4-negative	and	showed	only	 limited	signs	of	32
vacuolation	and	an	absence	of	koilocytosis.	One	area	was	 found	to	have	a	mitotic	 figure	higher	 than	33
2/3	of	the	epithelium.	Two	of	the	E4-negative	areas	were	in	the	endocervical glands,	(i.e. a	site	that	we	34
suspect	 does	 not	 support	 the	 ‘normal’	 productive	 life-cycle).	 All	 4	 E4-negative	 areas	 showed	 high	35
p16INK4a and	MCM	levels	up	to	or	above	2/3	of	the	epithelium,	suggesting	that	at	the	molecular	level	36
they	may	in	fact	be	CIN3-like.	37
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1
Re-classification	of	Ambiguous	Pathology	using	the	Dual	Marker	Approach2
To clearly	 assess	 how	 molecular	 patterns	 relate	 to	 pathology,	 we examined all 146	 total-3
agreement pathologies	 according	 to	 both	 E4	 status	 and	 distribution	 of	 p16INK4a (Fig	 6A).	 As	 each	4
pathology	 diagnosis	 was	 the	 consensus	 from three	 pathologists,	 the	 total	 number	 of	 individual	5
diagnostic	opinions	in this	group	was	438	(i.e.	3x146).	 	Lesions	classified	as	CIN1	and	which	express	6
E4 (Fig. 6A;	‘CIN1’	column (green)	left-most	graph))	are	supporting the	productive	phase	of	the	virus7
life	cycle,	and	typically	exhibit	limited p16INK4a expression.		Almost	all E4-positive	CIN1	were	however	8
positive	 for	 p16INK4a to	 some	 extent.	 	 By	 contrast,	 the	 majority	 of	 CIN3	 were	 E4-negative	 or	 very	9
limited	expression	(Fig.	6A	‘CIN3’ column (red)	right-most	graph) and	showed	a	much	more	extensive	10
p16INK4a distribution (i.e.	extending	through	2/3	of	the	epithelium), in	agreement	with	their	status	as11
transforming	rather	than	productive	infections.	Although	numbers	were	limited,	the total-agreement12
E4-negative	CIN2 generally	showed	a	more	 extensive	p16INK4a distribution	 than	was	seen	 in	 the E4-13
positive group.	 Although	clinical	practice	suggests	that	CIN2	and	CIN3	could	be	considered	together	as	14
HSIL,	 it	appears	 that	E4-positive	 ‘CIN1-like’	 lesions	are	more	common	 in	 the	CIN2	group	than	CIN3,	15
which	 reflects	 the	heterogeneity	of	CIN2.	The	E4	 and	p16INK4a biomarkers were absent	 in	nearly	 all	16
cases	where	 there	was	 total	agreement	 that	 the	pathology	was	not	HPV-associated and	had	another	17
cause (e.g.	metaplasia,	 inflammation	etc.).	 	 It	would	therefore	appear that	biomarker	patterns	reflect	18
the	underlying	pathology19
As	 part	 of	 our	 aim was	 to	 establish	 how	 molecular	 biomarkers	 might	 eventually	 improve	20
diagnostic	accuracy,	we	next	went	on	to	prepare a	second	chart,	but	this	time	included	the	384	cases	21
where	there was	partial	or	total pathology-disagreement	amongst	the	panel of	pathologists	(Fig.6B).	22
In	this	case,	the	total	number	of	individual	pathologies	examined	was	530	(384	+	146)	and	the	total	23
number	of	 individual	opinions	plotted	 in	Fig.6B	was	1590 (3	x	530).	 In areas considered	to	be	 low	24
grade by	at	least	one	pathologist, E4	expression	was	generally	accompanied	by low	levels	of	p16INK4a	,	25
similar	to the	total-agreement	group.	 Interestingly,	a significant	fraction	of	the	E4-negative	areas	were	26
found	to	be	p16INK4a-negative,	and	may	not	have	a	causal	association	with	HPV.	 	Non-viral	mimics	of	27
CIN1	could	include metaplasia	or	inflammation.	 	The	remaining	E4-negative	‘CIN1’	generally	showed	28
more	extensive	p16INK4a than	the	E4-positive	group.		29
The majority	 of	 areas	 that	 received	 a	 CIN2-classification	 were E4-negative,	 with	 levels	 of	30
p16INK4a expression higher	in	this	group	than	in	the	E4-positive	group. E4-positive	 ‘CIN2’ areas	were	31
equally divided	 according	 to	 whether	 E4	 expression	 was extensive, or	 restricted	 to	 focal	 regions	32
similar	 to	 those	 seen	 in	 the	 total-agreement	 CIN3	 category	 (Fig.6A).	 The	 E4-negative	 CIN2 that	33
express high	levels	of	p16INK4a	are	a	potentially	important	group	that	may	warrant	follow-up .		The	E4-34
positive	CIN3	typically	expressed	only	very	limited/focal	levels	of	E4, and	generally	showed extensive	35
p16INK4a expression supporting	the	high-grade	diagnosis.36
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A fraction	of	the	areas	classified	as	CIN2	or	CIN3	by	at	least	one	pathologist	lacked	expression	1
of	both	the	p16INK4a and	E4 biomarker, and	it	may	be	that	these	pathologies	are	not	HPV-associated.2
These	areas only	became	evident when	the	consensus	and	total	disagreements	were	combined,	hence	3
they	 can	 be	 considered	 as	 cases	 that	 are	 difficult	 to	 judge.	 Further	 analysis	 of	 these biomarker-4
negatives where	2	of	the	pathologists	agreed,	identified	2	CIN2	areas	judged	to	be	metaplasia	or	CIN3	5
by	the third	pathologist,	as	well	as 2	CIN3	areas	considered	to	be	metaplasia	or	CIN2.6
Amongst the	areas	where	there	was	total	disagreement between	the	panel	of	pathologists, 43	7
areas	were	p16INK4a-negative,	with	two of	these	being E4-positive,	although	the	extent	of	E4	expression	8
was	quite	restricted. The	majority	(41)	were	both E4 and	p16INK4a negative. One	of	our	pathologists	9
graded	 32 of these as	 non-CIN, in	 agreement	 with	 the	 E4/p16INK4a patterns,	 whereas	 another	10
pathologist	identified	24	CIN1	amongst	this	group	of	43	areas.	 In	15	out	of	these	24 pathology	areas,	a	11
different	grading	(CIN1,	CIN3	and	non-CIN (metaplasia/inflamation))	was	given	by	each	of	the	three	12
pathologists.		In	another	7	E4/	p16INK4a-negative areas,	all	three	pathologists	reported	the	presence	of	13
CIN,	but	each	gave	a	different	diagnosis	(CIN1,	CIN2,	CIN3).	 Such	inter-observer	variability	highlights14
the	 problem of reliably	 discriminating	 true	HPV-associated	 changes	 from	 other	 similar	 pathologies	15
such	 as	 metaplasia or inflammation, and	 supports our	 hypothesis	 that	 the	 staining	 of	 molecular	16
markers	 in	 addition	 to	 conventional	 pathology	 should	 help	 to improve	 overall	 diagnostic	 accuracy.		17
More	specifically,	our	data	suggest that	the molecular	patterns	seen	in	the	unequivocal	cases	(Fig.	6A),	18
and	which	 are	 likely	 to	 be true	 indicators of	 CIN	pathology,	 could	 be	 used	 to	 refine	 the	 grading	 of	19
disease	in	case	where	pathology-diagnosis	was equivocal (Fig.	6B).			20
21
22
Discussion	23
The	viral	aetiology	of	cervical	neoplasia	has	indicated	an	important	role	for	HPV	testing	during	24
cervical	 screening	 (1,	 39).	 HPV-negativity	means	 that	 screening	 intervals	 can	 be	 extended	 and	 that	25
there	is	a	low	risk	of	cancer	progression (40-43),	whereas	the	detection	of	HPV	DNA	highlights	a	need	26
for	 triage	 to	 establish	 the	 presence	 of	 active	 disease	 and	 to	 confirm	 its	 severity. The	 situation	 is	27
complicated	however	by	the	fact	that	transient	HPV	infections	that	are	not	likely	to	progress	to	cancer	28
are	 common	 in	 young	women,	 and	 that	 the	 presence	 of	 HPV	 in	 a	 cervical	 cytology	 or	whole	 tissue	29
biopsy	 sample	 does	 not	 necessarily	mean the	 presence	 of	 a	 precancerous	 lesion,	 and may	 in	 some	30
instances	represent	only	sexual	deposition	and	not	even	infection	(25).	As	a	result,	there	is	interest	in	31
the	use	of	biomarker	approaches	as	an	adjunct	to	pathology	in	order	to	confirm	infection	and	facilitate	32
disease	stratification.	Of	these,	p16INK4a has	been	most	well	characterised,	and	its	presence	in	cervical	33
neoplasia	 is	 generally	 taken	 as	 indicating	 deregulated	 HPV	 ‘oncogene	 expression’ (25,	 27,	 44).	34
Although	 the	 discrimination	 between	 high	 and	 low-grade	 cervical	 disease	 eventually	 determines	35
treatment	options,	robust	markers	of	low-grade	cervical	pathology	that	can	be	used	alongside	p16INK4a36
are	not	well	developed.	In	this	study	therefore,	we	considered	the	contribution	of	the	abundant	HPV-37
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encoded	E4	protein	in	discriminating	between	high	and	low	grade	disease	and	in	identifying	true	viral	1
infections	 from	 regions	 with	 similar	 pathology.	 An	 additional	 class	 of	 HPV	 E6/E7-induced	 cellular	2
protein	(MCM), similar	to	Ki-67, was	also	used	(45-47).	We	conclude	from	this	that	the	detection	of	E4	3
with	 p16INK4a provides	 additional	 molecular	 detail	 regarding	 the	 extent	 of	 HPV	 gene	 and	 life-cycle	4
deregulation,	and	that	such	a	dual	marker	approach	can	help	confirm	viral	aetiology	and	disease	status	5
in	both	high	and	low	grade	disease.6
To	 achieve	 the	 above	 goals,	we	 used	 a	 research/evaluation-methodology	 that	 allowed	 us	 to	7
superimpose	the	distribution	of	each	marker	onto	a	standard	H	&	E	stained	pathology	image,	allowing	8
us	 to	 correlate	 the	 features	 that	 are	 currently	 used for	 pathology	 diagnosis with	 the	 presence	 of	9
molecular	 markers.	 During	 this	 process,	 particular	 attention	 was	 paid	 to	 individual discrete	10
pathologies	found	in	each	lesion, in	order	to	establish	a	reference	of	how	each	biomarker	relates	to	the	11
underlying	pathology	of	 the	 tissue. From	 these	 focused	observations,	 a	 common	pattern	of	p16INK4a12
loss	 and	 E4	 appearance	was	 apparent as	 the	HPV	 infected	 cell	 underwent the	 process	 of	 epithelial	13
differentiation.	 	 In	 general,	 this correlated	 with	 the	 cytopathic	 effects	 that	 mark	 the	 onset	 of	14
productive	 infection	 during	 the	 process	 of	 koilocytosis	 and	 initiation	 of	 cell	 vacuolisation	 (8).15
Interestingly,	the	appearance	of	koilocytes	was	frequently	characterised	by	the	presence	of	abundant	16
E4	 in	 the	upper	epithelial	 layers,	 and	a	restriction	of	p16INK4a to	 the	 lower	 epithelial	 layers	within	a	17
lesion.	 	 This	 pattern	 of	 gene	 expression	was	 more	 reliably	 followed	 in	 low-grade	 than	 high-grade	18
disease.	 	 In	 general,	 difficulties	 in	 distinguishing	 normal	 squamous	 epithelium	 from	 low-grade	19
squamous	intraepithelial	lesions	(as	reported	by	McCluggage	&	Bharucha (48))	reflect	the	problem	of	20
discriminating	 between	 superficial	 vacuolated	 cells	 and	 true	 koilocytes.	 	 The	 observation	 that	 the	21
onset	of	E4	expression	coincides	with	the	appearance	of	vacuolated	cells	that	subsequently	go	on	to	22
form	 koilocytes	 as	 they	 differentiate	 may	 thus	 have	 diagnostic	 significance.	 In	 addition	 to	 this23
correlation	between	E4	expression	and	pathology,	we	noticed	a	clear	and	consistent	difference in the24
distribution	of	MCM,	which	is	considered	to	be	a	surrogate	marker	of	E6/E7	expression,	and	p16INK4a25
which	is	thought	to	be	an	indicator	of E6/E7	deregulation (Fig.	7) (25,	44,	49).	Again,	this	was	more	26
obvious	in	low-grade	pathologies	than	in	CIN3,	where	the	distribution	of	these	two	E6/E7	surrogates	27
was	in	most	cases	very	similar.	28
The	 underlying	 basis	 for	 the	 molecular	 biomarker	 patterns	 observed	 above	 can	 to	 a	 large	29
extent	be	drawn	from	our	understanding	of	HPV-driven	neoplastic	progression	and	normal	HPV	life-30
cycle	deregulation.	Thus	high	levels	of	E6	and	E7	can	stimulate	the	appearance	of	p16INK4a throughout	31
the	epithelium	by	interfering	with	the normal	functions	of	the	retinoblastoma	protein	(pRb)	and	the	32
KDM6	histone	demethylase	(16,	26).	Interestingly,	recent	studies	have	suggested	that	changes	in	viral	33
gene	expression	may	underlie	such	phenotypic	variation	in	CIN1	and	CIN2	(14),	but	that	host	genetic	34
changes	may	be	additionally	required	for	the	development	of	CIN3	(15).	The	MCM	marker,	as	shown	35
previously	for	Ki-67,	has	a	distinct	pattern	from	p16INK4a in	low-grade	disease,	presumably	because	its	36
induction	 marks	 the	 cell	 cycle	 entry	 that	 is	 ordinarily	 stimulated	 by	 HPV	 to	 allow	 genome	37
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amplification (see	Fig.	7) (12,	24,	49).	In	this	case,	cell	cycle	entry	associated	with	productive	infection	1
can be	distinguished	 from	 that	seen	 in	proliferating	 cells	 by	 the	detection	of	E4	 and	MCM	 together.		2
When	used	singly	however,	the	presence	of	markers	such	as	MCM	and	Ki-67	can	sometimes	be difficult	3
to	interpret,	as	these	proteins	may	also	be	up-regulated	during inflammation	and	metaplasia.	The	E4	4
biomarker	has	comparable	limitations	when	used	alone,	but	facilitates the	visualisation	of	most,	if	not	5
all HPV-associated	disease	areas	when	used	in	combination.	The	molecular	regulation	that	leads	to	E4	6
accumulation	has	previously	been	 investigated,	 and	 involves	deposition	of	E4	 in	 the	 infected	 cell	 as	7
amyloid	fibres,	at around	the	time	that	genome	amplification	begins	during	productive	infection	(50-8
52).	Precisely	why	productive	infection	and	E4	expression	are	retarded	in	high-grade	disease	is	only	9
poorly	understood	however,	although	our	recent	work	suggests	a	link	to	cell	cycle	duration,	and	the	10
accumulation	of	E4	only	as	the	G2	phase	of	cell	cycle	lengthens	(37,	53,	54).	These	preliminary	results	11
offer	 some initial	 insight	 as	 to	 why	 E4	 and	 p16INK4a produce	 largely	 complementary	 patterns	 of	12
staining	as	neoplastic	severity	increases.13
Although	the	pathology	overlay	analysis	clearly	shows	a	relationship	between	E4	abundance	14
and	regions	of	low-grade	pathology,	the	main	purposes	of	using	such	markers	is	to	improve	diagnostic	15
accuracy	 and	 to	determine	 the	most	 appropriate	 regimen for	 the	 treatment	of	disease.	 For	 cervical	16
neoplasia,	treatment	generally	follows	the	diagnosis	of	CIN2 or	higher,	and	typically	involves	surgical	17
removal	 of	 the	 infected	 tissue	 and	 disease	 margins	 (e.g.	 by	 cone	 biopsy).	 While	 this treatment	 is	18
generally	 effective	 in	 preventing	 neoplastic	 progression,	 such	 intervention	 has	 been	 linked	 to	 an	19
increased	risk	of	pre-term delivery	at	childbirth	(55,	56).	Current	thinking	also	suggests	that	there	is	20
considerable	 heterogeneity	 amongst	 CIN2,	 and	 that	 there	 is	 a	 significant	problem	 of	 overtreatment	21
within	 this	 group,	 partly	 accentuated	 by	 the	 difficulty	 of	 reliable	 diagnosis	 (57). From	 the	 work	22
described	here,	it	appears	that	lesions	designated	as	CIN2	by	one	or	more	pathologists	can	be	divided	23
into	two	groups	on	the	basis	of	whether	significant	E4	expression	is	retained	(i.e. they	are	CIN1-like),24
or	whether	E4	expression	is	lost	or	is	restricted	to	focal	areas	close	to	the	epithelial	surface	(i.e. they	25
are	 CIN3-like). In	 general,	 the	 absence	 or	 focal	 expression	 of	 the	 E4	 biomarker	 correlated with	26
established	 pathology	 features	 of	 high-grade	 disease,	 including	 high	 cell	 density	 that	 extended	27
towards	 the	 epithelial	 surface,	 the	 presence	 of	 cells	with	 a	 high	 nuclear	 to	 cytoplasmic	 ratio	 and	 a	28
more	extensive	p16INK4a expression	throughout	the	epithelium.	When	our	molecular	understanding	of	29
the	HPV	life-cycle	is	considered	alongside	these	pathology	correlations,	 it	would	seem	that	there	is	a	30
persuasive	 rationale	 for	 the	 use	 of	 a	 dual	 molecular	 marker	 approach	 alongside	 conventional	31
pathology	to	establish	disease	severity	and	the	associated	risk	of	cancer.32
For	routine	diagnostics,	an	additional	advantage	of	the	molecular	biomarkers	described	here	33
lies	 in	 their	 ease	 of	 use.	 Both	 p16INK4a and	MCM	 are	 already	 available	 commercially	 for	 diagnostic	34
purposes	 (49,	 58).	 Interestingly,	 several	 studies	 have	 advocated	 the	 use	 of	 HPV DNA in	 situ35
hybridisation	alongside	p16INK4a to	confirm	diagnosis (48,	59),	a	rationale	which given	the	correlation	36
between	E4	expression	and	viral	genome	amplification, has	some	similarities	to	the	E4/p16INK4a dual	37
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biomarker	 approach	 described	 here.	 Although	 E4	 detection	 reagents	 remain	 to	 be	 commercially	1
developed,	 it	 is	 the	most	 abundantly	 expressed	HPV	 protein	 during	 the	 viral	 life-cycle,	 and	 can	 be	2
detected	 in	 lesions	 without	 the	 need	 for	 signal	 amplification	 systems	 (28,	 33,	 53).	 The	 recent	3
development	of	a	new	pan-specific	HPV	E4	antibody that	is	broadly	cross-reactive	against	high-risk	E4	4
proteins	 should	 facilitate	 their	 further	 evaluation.	 It	 is	 generally	 realised	 that	 distinguishing	 high-5
grade	 HPV-induced	 disease	 from	 other	 events	 such	 as	 immature	 metaplasia,	 atypical	 immature	6
metaplasia	(AIM),	reactive/reparative	changes	or	atrophy	from	precancer	is	sometimes	impossible	on	7
the	basis	of	pathology	 alone.	 	 The	use	of	p16INK4a immunohistochemistry	and	detection	of	high-risk	8
HPV	can assist in	determining	viral	 aetiology and	has	 shown	 that	 a	proportion	of	 these	 lesions	 are	9
morphologically	difficult	 CIN3 (10).	The	 situation	with	 low-grade	 cervical	 disease	 is	 also	often	very	10
difficult.	 In	 the	 ASCUS-LSIL	 Triage	 Study (ALTS)	 for	 instance (60),	 only	 43%	 of	 biopsies	 initially	11
classified	 as	 low-grade	HPV-associated	 lesions	were	 classified	 as	 low-grade	disease	on	 review,	with	12
most	 discrepancies	 being	 explained	 by	 an	 inability	 of	 the	 pathologist	 panel	 to	 reliably	 discriminate	13
between	HPV-associated	disease,	reactive	squamous	proliferations,	and	other	situations	where	a	HPV-14
like	 low	 grade	 phenotype	 may	 be	 apparent	 (e.g.	 candidiasis,	 trichomoniasis). The	 vacuolated	 cells	15
shown	in	Fig.2B	(iii)	that	lack	markers	of	productive	HPV	infection	may	in fact	be	pseudokoilocytes.	16
Such	 issues	 contribute	 to	 the	 generally	 low	 inter-observer	 agreement	 in	 the	detection	of	 low-grade	17
HPV-associated	 disease,	which	 contrasts	 sharply	 with	 the	 excellent	 agreement	 for	 invasive	 cervical	18
lesions	and	even	high-grade	disease,	which	are	excellent	and	moderately	good	respectively.	As	shown	19
here,	 E4	 expression	 is	 typically	 associated	 with	 discrete	 pathology	 features	 of	 low-grade	 HPV-20
associated	 disease,	 and	 it	 has	 been	 suggested	 that	 careful	 attention	 to	 cytological	 and	 histological	21
changes	can	be	used	to	discriminate	between	viral	and	non-viral	pathologies	(10).	In	reality	however,	22
such	relatively	subtle	changes	are	not	easy	to	establish	under	routine	screening	conditions,	and	as	has	23
been	shown	for	all	of	the	markers	described	here,	their	use	not	only	marks,	but	also	draws	attention	to	24
the	region	of	abnormality.	In	our	study,	this	was	apparent	in	one	region	of	CIN3	that	was	missed	by	all	25
three	 pathologists,	 but	 was	 identified	 as	 being	 both	 p16INK4a- and	 MCM2-positive	 throughout	 the	26
epithelium	following	biomarker	analysis with confirmation	of	CIN3	status upon	pathology	review.		In	27
this	instance	the	CIN3	region	comprised	a	small	glandular	lesion	within	a	large	cone	biopsy.28
When	taken	together,	it	appears	that	conventional	pathology	combined	with	the	use	of	the E4	29
and	p16INK4a biomarkers has	advantages	over	pathology	alone,	or	the	use	of	pathology	in	combination	30
with	 p16INK4a staining	 for	 the	 stratification	 of	 HPV-associated	 cervical	 neoplasia,	 which	 already	31
provides	 information	 regarding	 clinical	 outcome	 (61).	 In	 particular,	 the	 use	 of	 E4	 facilitates	 the32
identification	 of	 low-grade	 viral	 disease where	 the	 protein	 is	 typically	 abundant,	 and	 distinguishes	33
such	cases	from	non-viral	pathologies	that	may	need	different	management	strategies.	Our	data	also	34
suggests	that	the	various	and	distinct	expression	patterns	of	both	p16INK4a and	E4	in	CIN2,	may	allow	35
categorisation	 of	 this	 heterogeneous	 group	 into	 a	 CIN1-like productive	 infection or	 a CIN3-like	36
transforming	 infection	group	according	 to	 the	 extent	 of	HPV	deregulation	 and	 life-cycle	 completion.	37
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We	cannot	be	sure	at	present	whether	this	would	help	in	determining	patient	management	strategies,	1
but	suspect	from	our	data	that	this	might	be	the	case.	The	abundance	of	E4	and	its	ease	of	detection,	2
should	facilitate	a	potential	role	during	routine	diagnosis	and	triage	following	cervical	screening.3
4
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Figure	Legends15
Figure	1.			Overlay	of	biomarker	patterns	onto	annotated	Hemotoxylin	and	Eosin	Pathology.16
A.	 	 Individual	 tissue	sections	were	subject	 to	 immunofluorescence	staining	 to	detect	the	biomarkers	17
E4	 using	 a	 TVG405-Alexa	 488	 conjugate	 (green),	 MCM	 using	 an	 anti-mouse	 Alexa	 594	 secondary	18
antibody	(red)	and	cellular	DNA	using	4’,6-Diamidino-2-Phenylindole (DAPI;	blue).	 	Individual	stains	19
were	recorded	digitally	at	high	resolution	(lower	panels)	before	the	section	was	processed	for	p16INK4a20
staining	and	development	in	3_Amino_9_ethylcarbazole	(AEC;	brown).	 	 	The	AEC	image	was	digitally	21
captured,	before	 the	 tissue	section	was	cleared	of	 the	AEC	substrate	and	stained	with	Carazzis	 (X2)	22
Hemotoxylin	 and	 Eosin.	 	 All	 H&E	 stained	 images	 were	 then	 examined	 independently	 by	 three	23
pathologists, and	 regions	with	 discrete	 pathology	 phenotypes	 recorded.	 	 The	 primary	 categories	 of	24
HPV-associated	pathology	comprised	CIN1,	CIN2	and	CIN3,	with	the	general	term	‘non-CIN’	being	used	25
to	 encompass	 a	 variety	of	non	HPV-associated	pathologies	 such	as	 inflammation	 and	metaplasia.	 A	26
‘normal’	classification	was	given	when	there	was	no	histological	abnormality.27
B.	 	 The	 3-colour	 immunofluorescence	 stain	 is	 shown	 on	 the	 left.	 	 Single	 channel	 coloured	 images	28
(collected	as	described	in	A)	were	extracted	from	the	immunofluorescence	image	or	from	the	p16INK4a29
AEC	stain	and	were	superimposed	onto	the	H&E	images	(under	the	heading	‘Pathology	overlay’).		The	30
simple	dual	marker	molecular	pathologies	(i.e.	not	overlayed	onto	the	H&E	image)	are	shown	on	the	31
right	to	reveal	the	relative	distributions	of	E4/MCM	and	E4/ p16INK4a (under	the	heading	‘Dual	marker	32
molecular	pathology).		The	image	shown	is	typical	of	those	used	to	prepare	the	more	detailed	images	33
of	neoplasias	used	in	subsequent	figures.	34
35
Figure	2.	 Distribution	of	the	HPV_E4,	p16INK4a and	MCM2	biomarkers	in	lesions	unambiguously	36
classified	as	CIN1.37
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A.		Biomarker	patterns	typically	associated	with	CIN1.		The	E4/MCM	(green/red)	biomarker	patterns	1
are	 shown	 in	 the	 immunofluorescence	 image	 to	 the	 left	 of	 the	 figure.	To	 facilitate	 comparison	with	2
lesional	 pathology,	 the	 E4/MCM	 (green/red)	 and	 p16INK4a (brown)	 biomarkers	 are	 overlayed	 onto	3
(and	shown	alongside)	the	basic	H	&	E	stain	in	the	central	part	of	the	figure.		The	E4/MCM	(green/red)	4
and	E4/ p16INK4a (green/brown)	biomarker	overlays	are	shown	separately	to	the	right	of	the	figure	so	5
that	 their	 relative	 distributions	 can	 be	 observed.	 	 	 The	 Biomarker	 patterns	 seen	 in	HPV	 associated	6
CIN1	are	described	below.7
i) Most	CIN1	are	productive	infections,	with	MCM	(red)	reaching	and	extending	into	the	E4	8
expressing	 layers	 (green).	 	 In	 this	 lesion,	 MCM	 and	 p16INK4a have	 broadly	 similar	9
distributions.10
ii) Although	 p16INK4a (brown)	 and	 MCM	 (red)	 expression	 can	 have	 different	 distributions,	11
MCM	again	extends	into	the	E4-positive	layers	(green).		In	this	lesion,	MCM	extends	higher	12
into	the	epithelial	layers	than	p16INK4a.13
iii) A	small	number	of	consensus	CIN1	(6/33)	failed	to	show	E4	(green)	biomarker	expression.	14
p16INK4a (brown)	expression	extends	into	the	upper	epithelial	layers	and	is	more	extensive	15
than	MCM	(red).16
B.	 	 Correlation	 of	 Biomarker	 patterns	 with	 Pathology.	 	 The	 E4/MCM	 (green/red)	 biomarker	17
distribution	in	consensus	CIN1	are	shown	as	immunofluorescence	images	to	the	left	of	the	figure,	and	18
overlayed	 onto	H	&	 E	 pathology	 towards	 the	 centre.	 	 The	 higher	magnification	 shown	 on	 the	 right	19
allows	correlation	of	specific	pathology	characteristics	with	the	accumulation	of	E4	and	the	decline	of	20
MCM.21
i) In	 the	 majority	 of	 CIN1,	 the	 E4	 (green)	 biomarker	 accumulates	 during	 the	 process	 of	22
koilocyte formation.	 	 Arrows	 labelled	 1	 to	 4	 show	 the	 progressive	 vacuolation that	23
accompanies	E4	accumulation	(beginning	at	arrow	2	and	highest	at	arrow	4),	and	the	loss	24
of	the	MCM	biomarker	(lowest	at	arrow	4).25
ii) Despite	 some	 differences	 in	 cell	 morphology	 and	 tissue	 architecture	 amongst	 CIN1,	 the	26
distribution	of	biomarkers	described	above	(i)	is	conserved.	27
iii) In	 one	 (out	 of	 33)	 consensus	 CIN1,	 koilocyte-like	 cells	 we	 present	 but	 were	 devoid	 of	28
markers	of	productive	infection,	 including	the	E4	(green)	biomarker	and	associated	MCM	29
(red)	staining.30
31
Figure	3.		Relevance	of	the	HPV_E4,	p16INK4a and	MCM	biomarkers	in	consensus	CIN3	lesions32
A.	 Biomarker	 Patterns	 Typically	 Associated	 with	 CIN3.	 	 The	 E4/MCM	 (green/red)	 and	 p16INK4a33
(brown)	biomarker	images	are	formatted	as	outlined	in	Fig.2A.		The	biomarker	patterns	seen	in	HPV-34
associated	CIN3	are	described	below.35
i) In	the	majority	of	CIN3,	the	E4	(green)	biomarker	is	absent,	and	both	the	MCM	(red)	and	36
p16INK4a (brown)	biomarkers	extend	uniformly	through	the	full	thickness	of	the	epithelium.		37
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ii) Despite	differences	in	lesion	size	and	morphology,	the	biomarker	patterns	described	above	1
(i)	were	broadly	similar	in	other	CIN3.2
B.	Expression	of	the	E4	biomarker	is	an	occasional	occurrence	in	CIN3.3
i) In	a	small	number	of	CIN3	(4/68),	focal	areas	of	E4	(green)	were	apparent.		Both	p16INK4a4
(brown)	and	MCM	(red)	extended	through	the	full	thickness	of	the	lesion	with	evidence	of	5
nuclear	crowding	as	seen	in	Fig	3A.		Panel	A	is	shown	enlarged	in	Fig.	3C.6
ii) In	 one	 case	 (out	 of	 68),	 the	 E4	 (green)	 biomarker	 was	 extensive,	 but	 was	 confined	 to	7
regions	 showing	 low-grade	 pathology	 that	 lacked	 strong	 p16INK4a (brown)	 biomarker	8
staining.		Panel	B	is	shown	enlarged	in	Fig.	3B.9
C.	 	 Pathology	 associated	 with	 E4	 expression	 in	 CIN3.	 	 	 The	 three	 images	 to	 the	 left	 show	 an	10
enlargement	of	Fig.	3B(i)	panel	A.		Although	vacuolated	cells	are	sometimes	apparent	in	CIN3	(arrows	11
marked	‘v’),	they	are	not	necessarily	associated	with	expression	of	the	E4	biomarker	(Fig.	2B(i)).		The	12
pathology	 associated	with	 E4	 expression	 in	 CIN3	 is	more	 clearly	 shown	 in	 the	 images	 to	 the	 right,	13
which	is	an	enlargement	of	panel	B	from	Fig.3B(ii).		This	region	of	low-grade	pathology	was	contained	14
within	the	CIN3	area.		The	pattern	of	vacuolation	and	koilocyte	formation	is	comparable	to	that	seen	in	15
CIN1	(Fig.	2B),	with	E4	expression	beginning	at	the	 first	sign	of	vacuolation	(arrows	 labelled	1)	and	16
becoming	prominent	as	the	MCM	biomarker	is	lost	(arrows	labelled	2).		17
18
Figure	4.	 	 	 	Expression	of	HPV_E4	along	with	p16INK4a and	MCM	suggests	two	categories	within	19
the	consensus	CIN2	group.20
A. HPV_E4-positivity	 amongst	 consensus	 CIN2.	 	 The	 E4/MCM	 (green/red)	 and	 p16INK4a (brown)	21
biomarker	 images	 are	 formatted	 as	outlined	 in	Fig.2A.	 	 The	biomarker	patterns	 seen	 in	E4-positive	22
HPV-associated	CIN2	are	described	below.23
i) High	cell	density	and	the	expression	of	MCM	precedes	the	accumulation	of	E4	in	a	subset	of	24
cells	showing	evidence	of	vacuolation.	P16INK4a and	MCM	expression	extend	throughout	the	25
full	thickness	of	the	epithelium.		Panel	A	is	enlarged	in	Fig.5.26
ii) Despite	 differences	 in	 epithelial	 thickness,	 the	 biomarker	 pattern	 is	 preserved	 in	 other	27
consensus	CIN2.28
iii) As	in	CIN1,	some	CIN2	show	a	more	extensive	expression	of	MCM	into	the	upper	epithelial	29
layers	when	compared	to	p16INK4a.	 	E4	expression	is	limited	to	cells	close	to	the	epithelial	30
surface.	 	 Panel	B	 is	 enlarged	 in	Fig.5	 to	 illustrate	 the	 correlation	between	pathology	 and	31
biomarker	patterns.32
B.		HPV_E4	negativity	amongst	consensus	CIN2.		33
i) Loss	 of	 the	 E4	 biomarker	 in	 a	 proportion	 of	 CIN2,	 can	 be	 associated	 with	 extensive	34
expression	of	the	p16INK4a /MCM	biomarkers	throughout	the	thickness	of	the	epithelium,	as	35
well	as	an	absence	of	obvious	differentiation	at	the	level	of	pathology.		Panel	C	is	enlarged	36
in	Fig.	5.37
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ii) MCM	can	extend	closer	throughout	the	epithelium	more	robustly	than	p16INK4a without	the	1
expression	of	 the	E4	biomarker.	 	The	panel	shown	 in	D	 is	enlarged	 in	Fig.	5	 to	show	the	2
absence	of	key	pathology	features	apparent	in	the	E4-positive	CIN2.	3
4
Figure	5.	 	 	Expression	of	 the	HPV_E4	biomarker	 in	CIN2	 is	associated	with	discrete	regions	of	5
CIN1-like	pathology.6
A.	7
i) Pathology	associated	with	E4	expression	in	CIN2.	 	 	The	six	images	show	enlargements of	8
the	regions	that	are	boxed	in	Fig.	4A(i)	and	(iii) (H&E	images).		The	pattern	of	vacuolation	9
and	 koilocyte	 formation	 is	 similar to	 that seen	 in	 CIN1	 (Fig.	 2B),	 with	 E4	 expression,	10
vacuolation	and	MCM	decline	coinciding	closely	(arrows	1&2).		11
B.12
ii) The	six	images	show	an	enlargement	of	the	regions	that	are	boxed	in	Fig	4B(i)	and	(ii).	In	13
these	 lesions,	 vacuolated	 cells	 are	 sometimes	 apparent	 (arrows	marked	 ‘v’),	 but are	 not	14
necessarily	associated	with	expression	of	the	E4	biomarker	(Fig.	4B(i)	and	(ii)).15
16
Figure	 6.	 	 	Division	 of	 Cervical	 Pathologies	 according	 to	 the	 Presence	 and	Distribution	 of	 the	17
Molecular	Markers	E4	and	p16INK4a	.18
19
A. Lesional	areas	where	there	was	total	agreement	amongst	the	panel	of	pathologists.		The	20
columns	 in	 each	 graph	 show the	 individual	 diagnostic	 opinions	 provided by	 the	 pathologist	21
panel after	review	of	 the	H&E	stained	slides,	as	either	non-CIN,	CIN1,	CIN2	or	CIN3.	 	Graphs	22
shown	 in	 A	 include	 only	 lesional	 areas	 where	 there	 was	 total	 agreement	 amongst	 the	23
pathologist	 panel.	 	 This	 standard	 pathology-grading	 is stratified	 according	 to	 whether	 the	24
diagnosed	areas	were subsequently	 found	to	be HPV-E4-positive	(green edged	columns/left-25
most graph)	 or	 E4-negative	 (red edged	 columns/right-most graph),	 and	 to	what	 extent the	26
p16INK4a expression extended	 through	 the	 epithelium. Lesional	 areas	 showing	 full	 thickness	27
p16	staining	are indicated	as dark brown columns,	with	lower	levels	of	staining	being	shown	in28
lighter	shades	of	brown.	 	 Lesional	areas	 that	 lacked	p16INK4a staining	are	 indicated	by	white	29
columns.	 In	general,	the	patterns	fit	with	our	current	model	of	life-cycle	deregulation	in	high-30
grade	neoplasia,	with	an	absence	of	both	markers	in	the	‘total-agreement’	non-CIN	group.		As	31
described	in	the	text,	E4	expression	in	CIN3	(marked	by	an	asterisk)	was	typically	sporadic	and	32
in	a	small	number	of	cells	close	to	the epithelial	surface.33
B. All	lesional	areas	including those	where	there	was	disagreement	amongst	the	panel	of	34
pathologists.	 The	 columns	 show	 the individual	 diagnostic	 opinions	 provided by	 the	35
pathologist	 panel	 on	 all	 lesional areas,	 irrespective	 of	 whether	 there	 was	 agreement	 or	36
disagreement	between	individual	pathologists.		Labelling	is	as	described	in	‘A’	above.	 Because	37
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the	 H&E-based	 diagnostic	 opinion	 often	 differed	 between	 the	 individual	 pathologists,	 the	1
pattern	 of	 the	 p16INK4a and	 E4	 staining	 typical	 of	 non-CIN,	 CIN1,	 CIN2	 and	 CIN3	 (shown	 in	2
Fig.6A)	is	less	apparent,	with	some	evidence	of	virus	infection	in	the	‘proposed’	non-CIN	group,	3
and	an	absence	of	biomarker	staining	in	some	‘proposed’ CIN1.4
5
Figure	 7.	 Molecular	 Principles	 Underlying	 the	 use	 of	 p16,	 MCM	 and	 E4	 as	 HPV-Associated	6
Disease	Biomarkers7
A.		In	uninfected	epithelium,	the	cellular	MCM	protein	(red)	is	usually	detectable	at	low	levels	only	in	8
the	 basal	 and	 parabasal cell	 layers	 as	 a	 result	 of	 cell-cycle	 stimulation	 by	 growth	 factors.	 	 This	9
facilitates	 the	 phosphorylation	 of	 pRb	 by	 cyclin-dependent	 kinases,	 the	 release	 of	 the	 E2F	10
transcription	 factor,	 and	 the	 regulated	 expression	 of	 MCM.	 	 	 During	 normal	 metaplasia	 or	 wound	11
healing,	MCM	may	also	be	detected	in	the	upper	epithelial	layers.	The	cellular	p16INK4a protein	is	also	12
stimulated	by	E2F,	but	does	not	usually	accumulate	 to	detectable	 levels	 in	uninfected	epithelium.	 	 It	13
provides	 feedback-regulation	 on	 the	 activity of	 cyclin-dependent	 kinases.	 p16INK4a is	 sometimes	14
visualised	as	a	weak	cytoplasmic	stain	in	cells	undergoing	senescence	(pale	brown).		The	HPV-encoded	15
E4	 protein	 is	 never	 expressed	 in	 uninfected	 epithelium	 and	 E4	 antibodies	 show	 no	 reactivity	with	16
cellular	proteins.17
B.			(i) In	HPV-infected	epithelial	tissue,	the	high-risk	E6	& E7	genes	(red)	are	expressed	together	from	18
the	viral	early	promoter	(PE),	and	function	to	drive	cell-cycle	entry	in	order	to	allow	cell	proliferation	19
and	 genome	 amplification.	 	 The	 high-risk	 E4	 gene	 (green)	 is	 expressed	 from	 a	 spliced	mRNA,	 and	20
becomes	abundant	following	the	activation	of	the	viral	late	promoter	(PL)	as	the	infected	cell	exits	the	21
cell	cycle	and	commits	to	true	differentiation.22
						(ii) E6	and	E7	are	expressed	at	low	level	in	the	cell,	but	the	consequences	of	their	presence	can	be	23
visualised	by	alterations	in	the	presence	of	p16INK4a and	MCM.		The	association	of	E7	with	pRb	leads	to	24
E2F	 release	 irrespective	 of	 growth	 factor	 stimulation.	 	 This	 allows	 MCM	 and	 also	 p16INK4a to	25
accumulate	 to	 higher	 levels	 than	 are	 typically	 seen	 in	 uninfected epithelium	 where	 expression	 is	26
dependent	 on	 cyclin-dependent	 kinase	 activation.	 	 The	 E7	 protein	 also	 acts	 to	 increase	 the	27
transcription	of	p16INK4a as	a	result	of	epigenetic	modification	of	the	p16INK4a promoter.		In	this	context,	28
p16INK4a and	MCM	can	be	used	with	caution	as	surrogate	markers	of	E6/E7	deregulation.29
					The	viral	E4	protein	becomes	abundant	in	the	upper	layers	of	HPV-infected	epithelium	as	a	result	of	30
viral	late	promoter	activation	and	the	cleavage	of	the	full-length	E4	protein	by	calpain.		Calpain-31
cleavage	exposes	a	C-terminal	multimerization	motif	in	E4,	which	allows	its	assembly	into	amyloid-32
like	fibres.		The	high-level	accumulation	of	E4-amyloid	is	thought to	coincide	with	progression	of	the	33
infected	cell	through	the	G2	phase	of	the	cell	cycle	and	eventually	to	cell-cycle	exit,	explaining	its	34
appearance	as	MCM	levels	decline.35
36
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